(NASDAQ: SNGX) Soligenix's forecast annual revenue growth rate of 7.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Soligenix's revenue in 2024 is $839,359.On average, 1 Wall Street analysts forecast SNGX's revenue for 2024 to be $8,419,550, with the lowest SNGX revenue forecast at $8,419,550, and the highest SNGX revenue forecast at $8,419,550. On average, 1 Wall Street analysts forecast SNGX's revenue for 2025 to be $10,524,437, with the lowest SNGX revenue forecast at $10,524,437, and the highest SNGX revenue forecast at $10,524,437.
In 2026, SNGX is forecast to generate $10,524,437 in revenue, with the lowest revenue forecast at $10,524,437 and the highest revenue forecast at $10,524,437.